Position in CELC
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$24,330,322
-$2,308,812 QoQ
Shares Held
232,559
-0.4% QoQ
Ownership
0.475%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#46
of 273 holders
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Focus Partners Wealth holds $223,220,139 across 78 Biotechnology names. CELC ranks #2 (10.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
128,958 | $64,057,307 | |
| 2 | CELC |
Celcuity Inc.
This page
|
232,559 | $24,330,322 | |
| 3 | ABVX |
Abivax S.A.
|
161,874 | $21,571,329 | |
| 4 | INCY |
Incyte Corp
|
161,917 | $18,354,911 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
163,036 | $12,760,827 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
147,917 | $11,728,338 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,043 | $8,756,372 | |
| 8 | EXEL |
Exelixis, Inc.
|
112,673 | $6,130,537 |
All Filings in CELC
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $24,330,322 | 232,559 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $26,639,134 | 233,390 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $23,419,650 | 234,807 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $11,601,244 | 234,843 | Shares | Sole | 2025-11-14 | |
| 2024-12-31 | $759,220 | 58,000 | Shares | Sole | 2025-05-20 | |
| 2024-09-30 | $864,780 | 58,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||